A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer (Argo)
Observational and Prospective Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER 2-Negative and Aggressive Disease Criteria
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08024
- Hospital Quiron Barcelona; Servicio de Oncologia
-
Granada, Spain, 18014
- Hospital Universitario Virgen de las Nieves; Servicio de Oncologia
-
Jaen, Spain, 23007
- Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
-
Leon, Spain, 24071
- Complejo Asistencial Universitario de Leon; Servicio de Oncologia
-
Lerida, Spain, 25198
- Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia
-
Lugo, Spain, 27003
- Hospital Lucus Augusti; Servicio de Oncologia
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre; Servicio de Oncologia
-
Madrid, Spain, 28006
- Hospital Universitario de la Princesa; Servicio de Oncologia
-
Madrid, Spain, 28033
- Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
-
Madrid, Spain, 28046
- Hospital Universitario La Paz; Servicio de Oncologia
-
Murcia, Spain, 30008
- Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia
-
Murcia, Spain, 30120
- Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
-
Navarra, Spain, 31008
- Hospital de Navarra; Servicio de Oncologia
-
Salamanca, Spain, 37007
- Hospital Clinico Universitario de Salamanca; Servicio de Oncologia
-
Segovia, Spain, 40002
- Hospital General de Segovia; Servicio de Oncologia
-
Sevilla, Spain, 41009
- Hospital Universitario Virgen Macarena; Servicio de Oncologia
-
Valencia, Spain, 46015
- Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
-
Valencia, Spain, 46017
- Hospital Universitario Dr. Peset; Servicio de Oncologia
-
Zamora, Spain, 49021
- Complejo Hospitalario Zamora- H. Virgen de la Concha; Servicio Oncologia
-
-
Castellon
-
Castellon de La Plana, Castellon, Spain, 12002
- Hospital Provincial de Castellon; Servicio de Oncologia
-
-
Cordoba
-
Córdoba, Cordoba, Spain, 14004
- Hospital Universitario Reina Sofia; Servicio de Oncologia
-
-
Guipuzcoa
-
San Sebastián, Guipuzcoa, Spain, 20014
- Hospital de Donostia.; Servicio de Oncología Radioterápica
-
-
Islas Baleares
-
Palma De Mallorca, Islas Baleares, Spain, 07014
- Hospital Universitario Son Espases; Servicio de Oncologia
-
-
LA Coruña
-
La Coruna, LA Coruña, Spain, 15006
- Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia
-
-
LAS Palmas
-
Las Palmas de Gran Canaria, LAS Palmas, Spain, 35016
- Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants with HER2-negative metastatic breast cancer. Mandatory to have the HER2/estrogen receptor (ER)/progesterone receptor (PR) status
- Participant who met criteria for first-line treatment with chemotherapy plus bevacizumab (standard doses) by local, regional or national guidelines or authorities
- Participants with measurable disease (RECIST criteria v1.1) or participants with no measurable but assessable disease
- Molecular phenotype as triple negative metastatic breast cancer; and ER-positive tumors need to fulfill at least one of the two clinical criteria: metastatic relapse on adjuvant endocrine therapy or progression to at least one prior line of endocrine therapy for advanced disease; or aggressive disease criteria (at least two criteria): taxane based regimen in the (neo) adjuvant setting; metastatic relapse within 2 years from the end of chemotherapy for early breast cancer; liver metastasis; three or more organs with metastatic involvement; symptomatic visceral disease
- Eastern Cooperative Oncology Group (ECOG) 0-2
Exclusion Criteria:
- Participant has received prior chemotherapy for metastatic disease
- Participant requiring major/minor surgery within 3 weeks prior to administration of the first dose of study treatment
- Participant has received an investigational therapy within 4 weeks prior to study entry
- Participant has known symptomatic brain metastases
- Participant with non-measurable or assessable disease: exclusive blastic bone disease; pleural, pericardial or abdominal effusion as only evidence of disease
- Participant in chronic daily treatment with corticosteroids (doses greater than [>]10 milligrams per day [mg/day] of methylprednisolone or equivalent), except inhaled steroids
- Pregnant or breastfeeding participant
- Women of childbearing potential who are not using hormonal contraceptives or highly effective birth control during the study
- Participant has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- Participant with significant renal, hematological or liver function alteration according to investigator's criteria
- Participant has serious medical risk factors involving any of the major organ systems
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Participants With Metastatic Breast Cancer
Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
|
Bevacizumab will be administered as per local clinical practice and local labeling.
Paclitaxel will be administered as per local clinical practice and local labeling.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Clinical Benefit
Time Frame: During follow-up (up to 18 months)
|
Clinical benefit was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1).
Clinical benefit is defined as partial or complete response as well as tumor stabilization for up to 24 weeks.
Results for clinical benefit were reported for 2 groups based on Circulating Tumor Cells (CTC) Levels.
The Sensitive group had CTC levels <5 (<5 CTCs in one of the two determinations) and Resistant group had CTC ≥5 (≥ 5 CTCs in the two determinations).
|
During follow-up (up to 18 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Overall Response as Assessed Using RECIST v1.1
Time Frame: From Baseline up to end of study (up to 18 months)
|
Overall response = Complete Response (CR) + Partial Response (PR).
Overall response was evaluated for the Sensitive group (CTC <5) and Resistant group (CTC ≥5).
|
From Baseline up to end of study (up to 18 months)
|
|
Progression Free Survival (PFS) as Assessed Using RECIST v1.1
Time Frame: From Baseline up to end of study (up to 18 months)
|
PFS was evaluated for the Sensitive group (CTC <5) and Resistant group (CTC ≥5).
|
From Baseline up to end of study (up to 18 months)
|
|
Overall Survival
Time Frame: From Baseline up to end of study (up to 18 months)
|
OS was evaluated for the Sensitive group (CTC <5) and Resistant group (CTC ≥5).
|
From Baseline up to end of study (up to 18 months)
|
|
Percentage of Participants With Adverse Events of Toxicity Grading 3 and/or 4
Time Frame: From Baseline up to end of study (up to 18 months)
|
Adverse events (AEs) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v 4.0).
Any AEs that are not specifically listed in the NCI CTCAE follow the logic - Grade 3) Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living; Grade 4: Life-threatening consequences or urgent intervention indicated.
|
From Baseline up to end of study (up to 18 months)
|
|
Optimal Cut-off for Clinical Benefit
Time Frame: Baseline (within 21 days prior to Day 1 Cycle 1), 7 days prior to Day 1 Cycle 3 (Cycle length = 28 days)
|
Clinical benefit was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1).
Clinical benefit is defined as partial or complete response as well as tumor stabilization for up to 24 weeks.
The optimal cut-off for clinical benefit was calculated from a Receiver Operating Curve (ROC) based on CTC level and used to define the prognostic factors that could better predict clinical outcomes.
|
Baseline (within 21 days prior to Day 1 Cycle 1), 7 days prior to Day 1 Cycle 3 (Cycle length = 28 days)
|
|
Percentage of Participants With Overall Response (OR) as Assessed Using RECIST v1. in Prognostic Groups
Time Frame: Baseline (within 21 days prior to Day 1 Cycle 1), 7 days prior to Day 1 Cycle 3 (Cycle length = 28 days)
|
Overall response = CR + PR.
An optimal cut-off point for the CTC count of 0.5 after 2 cycles of treatment was used to define the prognostic groups.
|
Baseline (within 21 days prior to Day 1 Cycle 1), 7 days prior to Day 1 Cycle 3 (Cycle length = 28 days)
|
|
PFS as Assessed Using RECIST v1. in Prognostic Groups
Time Frame: From Baseline up to end of study (up to 18 months)
|
An optimal cut-off point for the CTC count of 0.5 after 2 cycles of treatment was used to define the prognostic groups.
|
From Baseline up to end of study (up to 18 months)
|
|
Mean CTC Count Levels
Time Frame: Baseline (within 21 days prior to Day 1 Cycle 1 [Cycle length = 28 days])
|
CTC and CEA levels were compared to determine any correlation between the two.
Both CTC count at baseline and at cycle 2 were considered.
|
Baseline (within 21 days prior to Day 1 Cycle 1 [Cycle length = 28 days])
|
|
Mean Carcinoembryonic Antigen (CEA) Levels
Time Frame: Baseline (within 21 days prior to Day 1 Cycle 1 [Cycle length = 28 days])
|
Baseline (within 21 days prior to Day 1 Cycle 1 [Cycle length = 28 days])
|
|
|
Mean Biomarker Cancer Antigen 15.3 (CA 15.3) Level
Time Frame: Baseline (within 21 days prior to Day 1 Cycle 1 [Cycle length = 28 days])
|
CTC and CA 15.3 levels were compared to determine any correlation between the two.
Both CTC count at baseline and at cycle 2 were considered.
|
Baseline (within 21 days prior to Day 1 Cycle 1 [Cycle length = 28 days])
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Paclitaxel
- Bevacizumab
Other Study ID Numbers
Other Study ID Numbers
- ML29756
- ROC-BEV-2015-01 (Other Identifier: Hoffmann-La Roche)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.